Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Dutasteride vs HCG (Human Chorionic Gonadotropin): HCG (Human Chorionic Gonadotropin) has the stronger overall evidence (5.5 vs 5.4/10); the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
HCG (Human Chorionic Gonadotropin) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (1)
Outcomes where both Dutasteride and HCG (Human Chorionic Gonadotropin) have evidence — compare verdict strength side-by-side.
Approved BPH dose is 0.5 mg once daily; off-label hair-loss use mirrors the same 0.5 mg once-daily dose under a clinician. A prescription drug.
Any time of day
Oral soft-gel capsule (dutasteride 0.5 mg)
Prescription-only and indication-dependent. For intratesticular-testosterone maintenance on TRT, the cited studies used 125-500 IU every other day (intramuscular in the one that states the route). For spermatogenesis induction in hypogonadotropic hypogonadism, typically ~1,000-2,500 IU two to three times weekly (often combined with FSH), titrated to response. For female ovulation/oocyte-maturation trigger, a single dose (~5,000-10,000 IU urinary or 250 µg recombinant). No cited study gives these two doses. No dietary-supplement dose exists.
Any time of day
Prescription hCG — recombinant (choriogonadotropin alfa) or urinary-derived, by injection
and 1 more not shown
3–6 months
Months
Years
Weeks; may persist
Weeks
Months
Months
Within ~36 hours
The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
Journal of the American Academy of Dermatology (2006) · Rct · n=416
Randomized placebo-controlled trial of 416 men aged 21-45 comparing dutasteride 0.05, 0.1, 0.5 or 2.5 mg, finasteride 5 mg and placebo daily for 24 weeks
Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study.
Journal of the American Academy of Dermatology (2010) · Rct · n=153
Phase-III randomized double-blind placebo-controlled trial of 153 men over 6 months
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
European urology (2010) · Rct · n=4844
CombAT: 4-year multicenter randomized double-blind trial in 4,844 men aged 50 or over with symptomatic BPH and prostatic enlargement, comparing tamsulosin 0.4 mg, dutasteride 0.5 mg or both daily, with no placebo arm
Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression.
J Clin Endocrinol Metab (2005) · Rct · n=29
29 men with normal reproductive physiology randomized to weekly testosterone enanthate plus saline placebo or 125, 250, or 500 IU hCG every other day for 3 weeks
Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy.
J Urol (2013) · Observational · n=26
Retrospective cohort of 26 hypogonadal men on testosterone replacement plus 500 IU intramuscular hCG every other day, mean follow-up 6.2 months
A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin.
Fertil Steril (2009) · Observational · n=100
Combined analysis of four Phase III open-label studies in 100 men with complete idiopathic or acquired hypogonadotropic hypogonadism, pretreated with hCG for 3-6 months then hCG plus recombinant FSH
HCG (Human Chorionic Gonadotropin) has a higher evidence score (5.5/10 vs 5.4/10) and wins in 2 of 3 categories.
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.